奥扎格雷钠联合阿司匹林治疗急性脑梗死的临床疗效  

Clinical Efficacy of Ozagrel Sodium in Combination with Aspirin Treatment of Cerebral Infarction

作　　者：陈绍辉[1] 陈松深[1] 邱浩强[1] 李东航[1] 赖汉齐[1] 张和耀[1] 

机构地区：[1]南方医科大学附属普宁华侨医院神经内科,广东普宁515300

出　　处：《神经损伤与功能重建》2013年第5期337-339,共3页Neural Injury and Functional Reconstruction

摘　　要：目的:观察奥扎格雷钠联合阿司匹林对急性缺血性脑梗死患者的临床疗效及安全性。方法:84例急性缺血性脑梗死患者随机分为A组29例、B组28例、C组27例,分别给予阿司匹林、奥扎格雷钠、奥扎格雷钠联合阿司匹林治疗,观察用药14 d后3组的神经功能改善情况,并观察不良反应。结果:C组与A组和B组相比神经功能缺损评分及凝血指标降低显著,差异有统计学意义(P<0.05),临床疗效差异无统计学意义。用药前后肝肾功能无明显变化,不良反应发生率无明显差异。结论:奥扎格雷钠联合阿司匹林对于抗血小板聚集明显优于单用阿司匹林或奥扎格雷钠,具有良好的安全性。Objective： To observe the clinical efficacy and safety of Ozagrel Sodium in combination with Aspirin in the patients with cerebral infarction. Methods： Eighty-four cases with cerebral infarction were randomly divided into Aspirin group, Ozagrel Sodium group and Ozagrel Sodium in combination with Aspirin group respectively. The neurological function and the incidence of adverse reactions were assessed after treatment for 14 days. Results：Compared with Aspirin group, Ozagrel Sodium treatment group, the neurological function deficiency score and coagulation index of combinational treatment group were decreased significantly （P〈0.05）. There was no significant difference in clinical efficacy. No significant changes in kidney and liver functions appeared during treatment and the incidence of adverse reactions showed no difference. Conclusion： Ozagrel Sodium in combination with Aspirin on platelet aggregation was significantly superior to Aspirin or Ozagrel Sodium alone, with good safety in treatment of patients with cerebral infarction.

关 键 词：脑梗死 奥扎格雷钠 阿司匹林 血栓 血小板 

分 类 号：R741[医药卫生—神经病学与精神病学] R741.05[医药卫生—临床医学]